Technology | July 11, 2014

Cordis Launches Saber PTA Dilatation Balloon for Peripheral Arterial Disease

July 11, 2014 — Cordis Corp. announced the launch of its Saber PTA (percutaneous transluminal angioplasty) dilatation catheter for the treatment of patients with peripheral arterial disease (PAD). The Saber catheter is cleared for use and now available in Europe, the United States and Japan. This new product offers crossability and a comprehensive offering of balloon sizes on the widely used 0.018-inch over-the-wire (OTW) platform.

Developed to complement the Cordis PTA portfolio as a next-generation, high-performance workhorse 0.018-inch PTA balloon catheter, Saber is intended to dilate stenoses in iliac, femoral, ilio-femoral, popliteal, infrapopliteal and renal arteries and for the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae. The device is also indicated for post-dilation of balloon-expandable and self-expanding stents in the peripheral vasculature.

Saber is available in balloon diameters of 2-10 mm and lengths of 20-300 mm. It combines a durable dual layer hydrophilic coating with a low-profile body and new molded tip design to enhance crossability. The catheter has exceptional rated burst pressures of up to 18 atm due to its construction with Duralyn material

“In my initial experience with Saber catheter, I see outstanding crossability in very tight lesions as well as excellent deflation times,” said Peter Goverde, M.D., ZNA Antwerpen in Brussels, Belgium. “Given these performance characteristics combined with the size offering that Saber catheter provides, I see the value in adopting this as the preferred 0.018-inch workhorse balloon in my practice.”

“Saber catheter is the third new product launch from Cordis in the PAD space in the past 12 months, expanding our existing high-performance lower extremity portfolio, including the S.M.A.R.T. stent vascular line of products, such as our unique S.M.A.R.T. flex stent, and the highly differentiated specialty Chocolate balloon catheter,” said Celine Martin, president of Cordis. ”With the addition of both the Chocolate balloon catheter and extensive line of Saber catheter products, we’ve strengthened and deepened our overall offering in both the specialty and workhorse PTA segments.”

For more information: www.cordis.com

Related Content

Cardiovascular Systems Inc. and OrbusNeich Announce FDA Clearance  of Sapphire II Pro 1mm Coronary Balloon
Technology | Balloon Catheter | March 21, 2018
Cardiovascular Systems Inc. (CSI) recently announced that the U.S. Food and Drug Administration (FDA) has granted 510(k...
Cardiovascular Systems Expands Product Portfolio for Peripheral and Coronary Interventions
News | Balloon Catheter | January 24, 2018
Cardiovascular Systems Inc. recently announced two new partnerships broadening the company’s product portfolio. CSI is...
Abbott recalls its NC Balloon catheters
News | Balloon Catheter | May 22, 2017
May 22, 2017 — Abbott Vascular has initiated a voluntary recall of specific lots of three catheters due to 19 reports
Videos | Balloon Catheter | November 16, 2016
A discussion with Todd Brinton, M.D., about the newly FDA-cleared Shockwave Medical Lithoplasty System, at the Transc
NuCryo Vascular, Next Generation Cryoplasty Inflation Device, PolarCath Balloon Dilatation System

PolarCath Balloon Dilatation System image courtesy of NuCryo Vascular

Technology | Balloon Catheter | March 28, 2016
NuCryo Vascular LLC announced the launch of the Next Generation Cryoplasty Inflation device. The device received U.S....
NuCryo Vascular, FDA clearance, next-gen, PolarCath System, cryoplasty inflation device
Technology | Balloon Catheter | January 12, 2016
NuCryo Vascular LLC announced that they have received U.S. Food and Drug Administration (FDA) 510(k) clearance on the...
Videos | Balloon Catheter | October 30, 2015
Todd Brinton, M.D., clinical associate professor and consulting associate professor of bioengineering at Stanford Uni
Overlay Init